Last year, the FDA hit YMAB with a CRL for its neuroblastoma drug omburtamab. The company will need to do a new trial to get approval. Their restructuring will get them through mid-2024 with existing ...
Y-mAbs Therapeutics' naxitamab is approved for R/R High-Risk Neuroblastoma, with ongoing trials to expand its use, but the market size is limited. Financially, YMAB has a market cap of $644 million ...
In a recent study published in the Annals of Internal Medicine, researchers assess the efficacy of monoclonal antibodies (mAbs) in treating coronavirus disease 2019 (COVID-19) caused by different ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback